8-K ·Filed Jun 23, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001649094-26-000026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any future material changes to the board or strategy. This filing is routine and does not warrant any trading action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
PCVX ▲ +12.07% at T+60d
NEUTRAL call ✓ call won +12.07% · α vs SPY +9.23% · entry $53.87 → $60.37
Entry anchored
Jun 23, 03:59 PM ET
via exchange tick
T+1d
-0.35%
call -0.35% · α -0.50%
$53.68
settled 3mo ago
T+5d
+4.10%
call +4.10% · α +2.40%
$56.08
settled 3mo ago
T+20d
+3.95%
call +3.95% · α +2.02%
$56.00
settled 2mo ago
T+60d
+12.07%
call +12.07% · α +9.23%
$60.37
settled 15d ago

Price Chart

Loading chart...

Executive Summary

Vaxcyte announced the retirement of board member Jacks Lee and the appointment of Moncef Slaoui as an independent Class II director, effective June 17, 2026. Dr. Slaoui will receive standard non-employee director compensation, including an annual equity grant currently valued at $430,000. This is a routine governance filing with no material financial or operational impact.

Key Facts

  • Director Jacks Lee retired effective June 17, 2026; will remain as a consultant on supply and manufacturing.
  • Moncef Slaoui appointed as an independent Class II director; term expires at the 2028 annual meeting.
  • Dr. Slaoui receives standard director compensation; annual equity grant is currently set at $430,000.

Financial Impact

No material financial impact. Dr. Slaoui's annual director equity grant is $430,000, which is immaterial relative to Vaxcyte's $7.5B market cap.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001649094-26-000026
Document: 0001649094-26-000026-index-headers.html0001649094-26-000026
Document: 0001649094-26-000026-index.html0001649094-26-000026
Document: 0001649094-26-000026.txt0001649094-26-000026
13 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.92 $61.58▲ +10.12%▲ +10.72%$56.69 (+1.38%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jun 26, 2026
13w ago
144
NEUTRAL ★ 3/10
$57.72 $54.66▼ −5.30%▼ −5.02%$56.69 (−1.78%)
Jun 23, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$53.87 $56.00▲ +3.95%▲ +2.02%$56.69 (+5.23%)
Jun 19, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.11 $56.20▲ +7.85%▲ +8.00%$56.69 (+8.79%)
Jun 2, 2026
17w ago
Press Release
NEUTRAL ★ 4/10
$46.93 $58.39▲ +24.42%▲ +25.42%$56.69 (+20.80%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$51.48 $46.93▲ +8.84%▲ +11.97%$56.69 (−10.12%)
Apr 23, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $47.39▼ −20.34%▼ −24.37%$56.69 (−4.71%)
Apr 1, 2026
26w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $57.32▼ −2.02%▼ −11.74%$56.69 (−3.09%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access